Evommune (EVMN) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $5.17, -12.82% vs the prior close of $5.93.
- Volume 986.36K shares, 1.4x its 50-day average.
- New SEC filings: 4 (Oct 15, 2026).
- No new insider buys or sales reported since the prior session.
EVMN slides 12.8% to $5.17, a 52-week low. Closed at $5.17, -12.82% vs the prior close of $5.93. Day range $5.09–$5.96, opened at $5.97.
EVMN daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — EVMN slides 12.8% to $5.17, a 52-week low
- Closed at $5.17, -12.82% vs the prior close of $5.93. Day range $5.09–$5.96, opened at $5.97.
- Volume was 986.36K shares, 1.4x its 50-day average of 714.32K.
- Price is -50.8% vs its 50-day average ($10.51) and -71.9% vs its 200-day average ($18.40).
- 52-week range $5.09–$33.20; today's close sits at 0% of that range, 84.4% below the 52-week high.
Oct 15, 2026 — EVMN rises 2.8% to $5.93
- Closed at $5.93, +2.77% vs the prior close of $5.77. Day range $5.81–$6.00, opened at $5.90.
- Volume was 579.10K shares, 0.8x its 50-day average of 715.49K.
- Price is -44.4% vs its 50-day average ($10.67) and -67.9% vs its 200-day average ($18.46).
- 52-week range $5.64–$33.20; today's close sits at 1% of that range, 82.1% below the 52-week high.
Oct 14, 2026 — EVMN dips 1.9% to $5.77, a 52-week low, 4 down days in a row
- Closed at $5.77, -1.87% vs the prior close of $5.88. Day range $5.64–$5.96, opened at $5.79.
- Volume was 574.80K shares, 0.8x its 50-day average of 721.57K.
- Price is -46.6% vs its 50-day average ($10.81) and -68.8% vs its 200-day average ($18.52).
- 52-week range $5.64–$33.20; today's close sits at 0% of that range, 82.6% below the 52-week high.
- That makes 4 straight losses.
Oct 13, 2026 — EVMN dips 2.8% to $5.88, a 52-week low, 3 down days in a row
- Closed at $5.88, -2.81% vs the prior close of $6.05. Day range $5.85–$6.05, opened at $6.05.
- Volume was 804.90K shares, 1.1x its 50-day average of 722.72K.
- Price is -46.4% vs its 50-day average ($10.96) and -68.3% vs its 200-day average ($18.58).
- 52-week range $5.85–$33.20; today's close sits at 0% of that range, 82.3% below the 52-week high.
- That makes 3 straight losses.
Oct 12, 2026 — EVMN slides 3.2% to $6.05, a 52-week low
- Closed at $6.05, -3.20% vs the prior close of $6.25. Day range $6.04–$6.22, opened at $6.09.
- Volume was 384.00K shares, 0.5x its 50-day average of 721.10K — lighter than usual.
- Price is -45.4% vs its 50-day average ($11.08) and -67.5% vs its 200-day average ($18.63).
- 52-week range $6.02–$33.20; today's close sits at 0% of that range, 81.8% below the 52-week high.
Oct 9, 2026 — EVMN dips 2.5% to $6.25
- Closed at $6.25, -2.50% vs the prior close of $6.41. Day range $6.18–$6.44, opened at $6.40.
- Volume was 558.00K shares, 0.8x its 50-day average of 718.69K.
- Price is -44.1% vs its 50-day average ($11.18) and -66.6% vs its 200-day average ($18.69).
- 52-week range $6.02–$33.20; today's close sits at 1% of that range, 81.2% below the 52-week high.
Oct 8, 2026 — EVMN jumps 3.1% to $6.41
- Closed at $6.41, +3.05% vs the prior close of $6.22. Day range $6.02–$6.44, opened at $6.18.
- Volume was 692.00K shares, 1.0x its 50-day average of 711.01K.
- Price is -43.2% vs its 50-day average ($11.28) and -65.8% vs its 200-day average ($18.75).
- 52-week range $6.02–$33.20; today's close sits at 1% of that range, 80.7% below the 52-week high.
Oct 7, 2026 — EVMN slides 5.9% to $6.22, a 52-week low on 3.1x normal volume
- Closed at $6.22, -5.90% vs the prior close of $6.61. Day range $6.15–$6.53, opened at $6.51.
- Volume was 2.11M shares, 3.1x its 50-day average of 682.75K — unusually heavy trading.
- Price is -45.3% vs its 50-day average ($11.37) and -66.9% vs its 200-day average ($18.81).
- 52-week range $6.08–$33.20; today's close sits at 1% of that range, 81.3% below the 52-week high.
- That makes 9 straight losses.
Oct 6, 2026 — EVMN dips 0.6% to $6.61, a 52-week low, 8 down days in a row
- Closed at $6.61, -0.60% vs the prior close of $6.65. Day range $6.08–$6.67, opened at $6.67.
- Volume was 1.01M shares, 1.5x its 50-day average of 668.93K.
- Price is -42.4% vs its 50-day average ($11.48) and -64.9% vs its 200-day average ($18.85).
- 52-week range $6.08–$33.20; today's close sits at 2% of that range, 80.1% below the 52-week high.
- That makes 8 straight losses.
Oct 5, 2026 — EVMN slides 3.9% to $6.65, a 52-week low on 2.1x normal volume
- Closed at $6.65, -3.90% vs the prior close of $6.92. Day range $6.52–$7.22, opened at $6.86.
- Volume was 1.37M shares, 2.1x its 50-day average of 647.11K — unusually heavy trading.
- Price is -42.5% vs its 50-day average ($11.57) and -64.8% vs its 200-day average ($18.90).
- 52-week range $6.52–$33.20; today's close sits at 0% of that range, 80.0% below the 52-week high.
- That makes 7 straight losses.
Oct 2, 2026 — EVMN slides 4.0% to $6.92, a 6-month low on 2.8x normal volume
- Closed at $6.92, -4.02% vs the prior close of $7.21. Day range $6.74–$7.28, opened at $7.25.
- Volume was 1.75M shares, 2.8x its 50-day average of 628.76K — unusually heavy trading.
- Price is -40.7% vs its 50-day average ($11.67) and -63.5% vs its 200-day average ($18.94).
- 52-week range $6.74–$33.20; today's close sits at 1% of that range, 79.2% below the 52-week high.
- That makes 6 straight losses.
EVMN latest news & SEC filings
Every SEC filing by or about EVMN in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 15, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Pena Luis C. received an award of 1,115 shares at $7.02 (≈$7.83K) on Sep 30, 2026; now holds 631,573
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 1, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Sep 23, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Sep 15, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Sep 9, 2026 · Form 424B3 — Prospectus / supplement for an offering or resale
Prospectus / supplement for an offering or resale
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Sep 9, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
- Item 8.01 — Reported other events the company considers important.
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 14, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 6, 2026 · Form 424B3 — Prospectus / supplement for an offering or resale
Prospectus / supplement for an offering or resale
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Aug 6, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $0 (prior year $0)
- Net income: -$32.25M (prior year -$13.56M) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$0.89 (prior year -$8.80) (loss narrowed vs Jun 30, 2025)
Aug 6, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Jul 30, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Jul 16, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jul 10, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Carver Kyle bought 1,000 shares at $13.26 (≈$13.26K) on Jul 8, 2026
- Carver Kyle bought 1,000 shares at $13.26 (≈$13.26K) on Jul 8, 2026
- Carver Kyle bought 1,000 shares at $13.26 (≈$13.26K) on Jul 8, 2026
- Carver Kyle bought 1,000 shares at $13.26 (≈$13.26K) on Jul 8, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Jul 8, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Kirsch Arthur S bought 10,000 shares at $13.30 (≈$133.00K) on Jul 7, 2026
- Kirsch Arthur S bought 10,000 shares at $13.30 (≈$133.00K) on Jul 7, 2026
- Kirsch Arthur S bought 10,000 shares at $13.30 (≈$133.00K) on Jul 7, 2026
- Kirsch Arthur S bought 10,000 shares at $13.30 (≈$133.00K) on Jul 7, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Things to know before you trade EVMN
- Last results release: Aug 6, 2026 (8-K Item 2.02). Previous ones: May 7, 2026, Mar 5, 2026, Dec 11, 2025. Based on that rhythm, the next report is likely around Nov 5, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 3.75% (largest 12.8%). That is a volatile stock.
- Liquidity: about 905.28K shares (≈$4.68M) trade per day on average.
- 52-week position: $5.17 vs a range of $5.09–$33.20 (0% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 8 open-market buys, 17 sales; latest: Kyle Carver bought 1,000 shares on Jul 8, 2026.
- Latest filings: 8-K Oct 1, 2026; 8-K Sep 23, 2026; 8-K Sep 15, 2026.
- Listing: NYSE · industry: Pharmaceutical Preparations.
EVMN market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 5.97 | 5.96 | 5.09 | 5.17 | 986.36K |
| Oct 15, 2026 | 5.90 | 6.00 | 5.81 | 5.93 | 579.10K |
| Oct 14, 2026 | 5.79 | 5.96 | 5.64 | 5.77 | 574.80K |
| Oct 13, 2026 | 6.05 | 6.05 | 5.85 | 5.88 | 804.90K |
| Oct 12, 2026 | 6.09 | 6.22 | 6.04 | 6.05 | 384.00K |
| Oct 9, 2026 | 6.40 | 6.44 | 6.18 | 6.25 | 558.00K |
| Oct 8, 2026 | 6.18 | 6.44 | 6.02 | 6.41 | 692.00K |
| Oct 7, 2026 | 6.51 | 6.53 | 6.15 | 6.22 | 2.11M |
| Oct 6, 2026 | 6.67 | 6.67 | 6.08 | 6.61 | 1.01M |
| Oct 5, 2026 | 6.86 | 7.22 | 6.52 | 6.65 | 1.37M |
| Oct 2, 2026 | 7.25 | 7.28 | 6.74 | 6.92 | 1.75M |
| Oct 1, 2026 | 8.25 | 8.30 | 6.99 | 7.21 | 1.52M |
| Sep 30, 2026 | 8.40 | 8.52 | 8.11 | 8.26 | 720.20K |
| Sep 29, 2026 | 8.36 | 8.65 | 8.11 | 8.35 | 807.60K |
| Sep 28, 2026 | 8.40 | 8.44 | 8.12 | 8.39 | 660.80K |
| Sep 25, 2026 | 8.78 | 8.78 | 8.33 | 8.49 | 541.10K |
| Sep 24, 2026 | 8.73 | 8.90 | 8.25 | 8.80 | 992.20K |
| Sep 23, 2026 | 9.48 | 9.54 | 8.69 | 8.77 | 872.40K |
| Sep 22, 2026 | 9.45 | 9.86 | 9.39 | 9.60 | 573.80K |
| Sep 21, 2026 | 9.70 | 9.70 | 9.35 | 9.45 | 603.00K |
About Evommune
Evommune (EVMN) is listed on the NYSE and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in PALO ALTO, CA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 2044725.
EVMN board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Eugene Bauer | Chief Medical Officer | Apr 17, 2026 |
| David E Cohen | Director | Jun 3, 2026 |
| Derek Dirocco | Director | Nov 5, 2025 |
| Robert Lorne Hopfner | Director | Dec 22, 2025 |
| Arthur S Kirsch | Director | Jul 8, 2026 |
| Peter Kolchinsky | Director | Feb 17, 2026 |
| 7 Cooperative Ua Lsp | Director | Feb 19, 2026 |
| Benjamin F Iii Mcgraw | Director | Jun 3, 2026 |
| Luis C. Pena | President & CEO | Jun 24, 2026 |
| Bioventure Partners Fund I G.P., L.P. Pivotal | Director | Nov 12, 2025 |
| Bioventure Partners Fund I U.G.P. Ltd Pivotal | Director | Nov 12, 2025 |
| Bioventure Partners Fund I, L.P. Pivotal | Director | Nov 12, 2025 |
| Capital Management, L.P. Ra | Director | Feb 17, 2026 |
| Capital Healthcare Fund Lp Ra | Director | Feb 17, 2026 |
| Capital Nexus Fund Iii, L.P. Ra | Director | Feb 17, 2026 |
| Rajeev M. Shah | Director | Feb 17, 2026 |
| Weegen Felice Isabel Verduyn-Van | Director | Feb 18, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Eugene Bauer | Chief Medical Officer | Apr 17, 2026 |
| Kyle Carver | Chief Financial Officer | Jul 10, 2026 |
| Janice Suzann Drew | Chief of Dev. Operations | Jun 24, 2026 |
| Gregory S. Moss | Chief Business & Legal Officer | Jun 1, 2026 |
| Jeegar Pravinkumar Patel | Chief Scientific Officer | Jun 24, 2026 |
| Luis C. Pena | President & CEO | Jun 24, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jul 8, 2026 | Kyle Carver | Buy | 1,000 | $13.26 |
| Jul 8, 2026 | Kyle Carver | Buy | 1,000 | $13.26 |
| Jul 8, 2026 | Kyle Carver | Buy | 1,000 | $13.26 |
| Jul 8, 2026 | Kyle Carver | Buy | 1,000 | $13.26 |
| Jul 7, 2026 | Arthur S Kirsch | Buy | 10,000 | $13.30 |
| Jul 7, 2026 | Arthur S Kirsch | Buy | 10,000 | $13.30 |
| Jul 7, 2026 | Arthur S Kirsch | Buy | 10,000 | $13.30 |
| Jul 7, 2026 | Arthur S Kirsch | Buy | 10,000 | $13.30 |
| Jun 22, 2026 | Janice Suzann Drew | Sale | 20,000 | $22.63 |
| Jun 22, 2026 | Janice Suzann Drew | Sale | 20,000 | $22.63 |
| Jun 22, 2026 | Janice Suzann Drew | Sale | 20,000 | $22.63 |
| Jun 22, 2026 | Janice Suzann Drew | Sale | 20,000 | $22.63 |
| Jun 22, 2026 | Jeegar Pravinkumar Patel | Sale | 1,488 | $22.50 |
| Jun 22, 2026 | Jeegar Pravinkumar Patel | Sale | 1,488 | $22.50 |
| Jun 22, 2026 | Jeegar Pravinkumar Patel | Sale | 1,488 | $22.50 |
EVMN financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $13.00M | $-68.87M | -11.22 | $-76.44M |
| Dec 31, 2024 | $7.00M | $-66.81M | -45.29 | $-58.20M |
Latest balance sheet: total assets $301.95M, total liabilities $24.36M, cash $60.03M (as of Jun 30, 2026).
EVMN earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 6, 2026 | 8-K Item 2.02 (results) | $13.38 |
| May 7, 2026 | 8-K Item 2.02 (results) | $22.50 |
| Mar 5, 2026 | 8-K Item 2.02 (results) | $25.09 |
| Dec 11, 2025 | 8-K Item 2.02 (results) | $19.69 |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on EVMN
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.